General: Edoxabn is a reversible factor Xa inhibitor with high selectivity. During coagulation, factor Xa forms a prothrombinase complex with factor Va on the surface of platelets . Prothrombinase converts prothrombin to thrombin, which in turn converts soluble fibrinogen to insoluble fibrin, the main component of blood clots. Thus, FXa has become a major target for the development of a new generation of anticoagulants.

Product introduce：Edoxabn is a selective factor Xa inhibitor with Ki of 0.561 nM, >10 000-fold selectivity over thrombin and FIXa, and is also an orally bioavailable anticoagulant drug.

Function： Edo xaban can be used to prevent serious blood clots from forming due to some irregular heartbeat (atrial fibrillation). It is also used to treat certain blood clots.  It is an anticoagulant, which works by blocking some coagulation proteins in the blood.

Origin: On January 8, 2015, the US Food and Drug Administration (FDA) approved a brand, an anticoagulant drug from the Daiichi Sankyo Company Limited，TYO: 4568 , to reduce the risk of stroke and dangerous thrombosis (systemic embolism) in patients with atrial fibrillation caused by non-valvular heart disease.

Researchers led by Dr. Robert Giugliano, a cardiologist at Boston brigham Women's Hospital, introduced at the scientific meeting of American Heart Association held in Dallas that a new anticoagulant, Edoxban, developed by the Daiichi Sankyo Co., Ltd., was more effective in preventing blood clots and strokes than the widely used one in a large-scale later clinical trial, and the risk of bleeding was significantly lower than that of Favalin.